SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+FoxP3+ T regulatory cells by production of IFN-γ

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Madireddi, Shravan ^a   Schabowsky, Rich Henry ^a   Srivastava, Abhishek K ^a   Sharma, Rajesh K ^a   Yolcu, Esma S ^a   Shirwan, Haval ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; SA 4 1BBL RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; BIOTRANSFORMATION; CANCER IMMUNOLOGY; CD4+ FOXP3+ T REGULATORY CELL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE EVASION; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR MODEL;

4-1BB LIGAND; ANIMALS; ANTIGENS, CD137; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOTHERAPY; INTERFERON-GAMMA; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

ERAGROSTIS TEF;

EID: 84864749497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042459     Document Type: Article

References (39)

1. Zou W, (2006) Regulatory T cells, tumour immunity and immunotherapy. Nature reviews Immunology 6: 295-307.
2. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature medicine 10: 942-949.
3. Chen W, Jin W, Hardegen N, Lei KJ, Li L, et al. (2003) Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. The Journal of experimental medicine 198: 1875-1886.
4. Valzasina B, Piconese S, Guiducci C, Colombo MP, (2006) Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer research 66: 4488-4495.
5. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, et al. (2010) Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer research 70: 7788-7799.
6. Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, et al. (2010) Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer research 70: 7800-7809.
7. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. Journal of immunology 169: 2756-2761.
8. Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, et al. (2010) Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clinical cancer research: an official journal of the American Association for Cancer Research 16: 5067-5078.
9. Powell DJ Jr, Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, et al. (2007) Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. Journal of immunology 179: 4919-4928.
10. Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, et al. (1997) 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. The Journal of experimental medicine 186: 47-55.
11. Croft M, (2009) The role of TNF superfamily members in T-cell function and diseases. Nature reviews Immunology 9: 271-285.
12. Sharma RK, Schabowsky RH, Srivastava AK, Elpek KG, Madireddi S, et al. (2010) 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer research 70: 3945-3954.
13. Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, et al. (2009) Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer research 69: 4319-4326.
14. Watts TH, (2005) TNF/TNFR family members in costimulation of T cell responses. Annual review of immunology 23: 23-68.
15. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, et al. (2005) Inducing and expanding regulatory T cell populations by foreign antigen. Nature immunology 6: 1219-1227.
16. Schabowsky RH, Elpek KG, Madireddi S, Sharma RK, Yolcu ES, et al. (2009) A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine 28: 512-522.
17. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, et al. (2004) Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. Journal of immunology 172: 5149-5153.
18. Liu VC, Wong LY, Jang T, Shah AH, Park I, et al. (2007) Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. Journal of immunology 178: 2883-2892.
19. Xiao X, Kroemer A, Gao W, Ishii N, Demirci G, et al. (2008) OX40/OX40L costimulation affects induction of Foxp3+ regulatory T cells in part by expanding memory T cells in vivo. Journal of immunology 181: 3193-3201.
20. Yu P, Lee Y, Liu W, Krausz T, Chong A, et al. (2005) Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. The Journal of experimental medicine 201: 779-791.
21. Melero I, Murillo O, Dubrot J, Hervas-Stubbs S, Perez-Gracia JL, (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends in pharmacological sciences 29: 383-390.
22. Choi BK, Bae JS, Choi EM, Kang WJ, Sakaguchi S, et al. (2004) 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. Journal of leukocyte biology 75: 785-791.
23. Zhang P, Gao F, Wang Q, Wang X, Zhu F, et al. (2007) Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression. Scandinavian journal of immunology 66: 435-440.
24. Zheng G, Wang B, Chen A, (2004) The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells. Journal of immunology 173: 2428-2434.
25. Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, et al. (2007) Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. Journal of immunology 179: 7295-7304.
26. Wei J, Duramad O, Perng OA, Reiner SL, Liu YJ, et al. (2007) Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America 104: 18169-18174.
27. Hill JA, Hall JA, Sun CM, Cai Q, Ghyselinck N, et al. (2008) Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+CD44hi Cells. Immunity 29: 758-770.
28. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S, (2002) Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nature immunology 3: 135-142.
29. Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, et al. (2004) Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. Journal of immunology 173: 5008-5020.
30. Piconese S, Valzasina B, Colombo MP, (2008) OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. The Journal of experimental medicine 205: 825-839.
31. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, et al. (2005) Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105: 2845-2851.
32. Vu MD, Xiao X, Gao W, Degauque N, Chen M, et al. (2007) OX40 costimulation turns off Foxp3+ Tregs. Blood 110: 2501-2510.
33. Duan W, So T, Croft M, (2008) Antagonism of airway tolerance by endotoxin/lipopolysaccharide through promoting OX40L and suppressing antigen-specific Foxp3+ T regulatory cells. Journal of immunology 181: 8650-8659.
34. Dawicki W, Bertram EM, Sharpe AH, Watts TH, (2004) 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. Journal of immunology 173: 5944-5951.
35. Sharma RK, Srivastava AK, Yolcu ES, MacLeod KJ, Schabowsky RH, et al. (2010) SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. Vaccine 28: 5794-5802.
36. Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, et al. (2007) Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. Journal of immunology 178: 4194-4213.
37. Lee SW, Salek-Ardakani S, Mittler RS, Croft M, (2009) Hypercostimulation through 4-1BB distorts homeostasis of immune cells. Journal of immunology 182: 6753-6762.
38. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, et al. (1997) Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature medicine 3: 682-685.
39. Kwon BS, Hurtado JC, Lee ZH, Kwack KB, Seo SK, et al. (2002) Immune responses in 4-1BB (CD137)-deficient mice. Journal of immunology 168: 5483-5490.